Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Warner Chilcott



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Warner Chilcott rose 19 cents (1.4%) to $13.50 on heavy volume. Throughout the day, 8.3 million shares of Warner Chilcott exchanged hands as compared to its average daily volume of 4.6 million shares. The stock ranged in a price between $13.18-$13.57 after having opened the day at $13.27 as compared to the previous trading day's close of $13.31. Other companies within the Drugs industry that increased today were:

Prima Biomed Ltd. ADR



), up 19.5%,

AEterna Zentaris



), up 14.4%,

Cytori Therapeutics



), up 14.3%, and

Savient Pharmaceuticals



), up 12.1%.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in women's healthcare, gastroenterology, dermatology, and urology segments in North America and western Europe markets. Warner Chilcott has a market cap of $3.33 billion and is part of the

health care

sector. The company has a P/E ratio of 13.3, above the average drugs industry P/E ratio of 11.7 and below the S&P 500 P/E ratio of 17.7. Shares are down 2.1% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Warner Chilcott a buy, one analyst rates it a sell, and four rate it a hold.

TheStreet Ratings rates Warner Chilcott as a


. The company's strengths can be seen in multiple areas, such as its expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and weak operating cash flow.

On the negative front,

MEI Pharma


TheStreet Recommends


), down 20.5%,

Aoxing Pharmaceutical Company



), down 13.3%,

Peregrine Pharmaceuticals



), down 7.2%, and




), down 6.9%, were all laggards within the drugs industry with

Abbott Laboratories



) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now